Octreotide HCl
| Code | Size | Price |
|---|
| TAR-T2584L1-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T2584L1-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Documents
Further Information
Bioactivity:
Octreotide HCl is a potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits the secretion of growth hormone.
CAS:
1607842-55-6
Molecular Weight:
1092.16
Purity:
0.98
SMILES:
O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@H](CO)[C@H](O)C)=O)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC3=CC=CC=C3)N[C@@H]1CC4=CNC5=CC=CC=C45.Cl.Cl
References
Hvas CL, Ott P, Paine P, Lal S, J?rgensen SP, Dahlerup JF. Obeticholic acid for severe bile acid diarrhea with intestinal failure: A case report and review of the literature. World J Gastroenterol. 2018 Jun 7;24(21):2320-2326. doi: 10.3748/wjg.v24.i21.2320. PubMed PMID: 29881241; PubMed Central PMCID: PMC5989246.
Luo Y, Chen J, Shen B, Wang M, Cai H, Xu L, Chen L, Chen M, Li ZP, Feng ST. CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold? Eur Radiol. 2018 Jun 6. doi: 10.1007/s00330-018-5512-1. [Epub ahead of print] PubMed PMID: 29876704.
Ramesh S, Kudachi S, Basu S. PRRT with (177)Lu-DOTATATE in Carcinoid Heart Disease: a contraindication or a promising treatment approach bettering chances for corrective surgery? J Nucl Med Technol. 2018 Jun 8. pii: jnmt.118.210179. doi: 10.2967/jnmt.118.210179. [Epub ahead of print] PubMed PMID: 29884687.
Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E; NETTER-1 Study Group. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With (177)Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018 Jun 7:JCO2018785865. doi: 10.1200/JCO.2018.78.5865. [Epub ahead of print] PubMed PMID: 29878866.